Loading..

Vericel Corporation (VCEL) Report Analysis

Corporate Events

Neutral

Vericel Corporation has filed a Shelf Registrat...

2022-05-06 00:00:00

Vericel Corporation has filed a Shelf Registration in the amount of $78.43 million. Security Name: Common Stock Securities Offered: 2,750,...

Neutral

Vericel Corporation Reaffirms Earnings Guidance...

2022-05-04 11:55:00

Vericel Corporation reaffirmed earnings guidance for the year 2022. Total net revenue for 2022 expected to be in the range of $178 to $189 mil...

Neutral

Vericel Corporation, Q1 2022 Earnings Call, May...

2022-04-20 12:30:00

Vericel Corporation, Q1 2022 Earnings Call, May 04, 2022

Neutral

Vericel Corporation, Annual General Meeting, Ap...

2022-03-17 12:27:00

Vericel Corporation, Annual General Meeting, Apr 27, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider election of directors; to ap...

Neutral

Vericel Corporation - Shareholder/Analyst Call

2022-03-17 12:27:00

AGM

Positive

Vericel Corporation Announces Plans for A New C...

2022-02-02 21:05:00

Vericel Corporation announced that it has entered into a long-term lease agreement for a new cell therapy manufacturing and corporate headquar...

Neutral

Vericel Corporation Presents at 15th Annual Can...

2021-11-12 12:04:00

Vericel Corporation Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 10:00 AM. ...

Neutral

Vericel Corporation Provides Earnings Guidance ...

2021-11-09 12:40:00

Vericel Corporation provided earnings guidance for the full year of 2021. For the year, the company's total net revenue is now expected to inc...

Neutral

Vericel Corporation to Report Q3, 2021 Results ...

2021-10-21 12:30:00

Vericel Corporation announced that they will report Q3, 2021 results on Nov 09, 2021

Neutral

Vericel Corporation, Q3 2021 Earnings Call, Nov...

2021-10-21 12:30:00

Vericel Corporation, Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Canaccord Genuity LLC, 15th Annual Canaccord Ge...

2021-10-14 22:02:00

Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021.

Neutral

Vericel Corporation Presents at 2021 Veeva R&D ...

2021-09-14 11:35:00

Vericel Corporation Presents at 2021 Veeva R&D and Quality Summit Connect, Oct-14-2021 01:30 PM. Speakers: Craig Gassman, Sr. Director, Corpor...

Neutral

Veeva Systems Inc., 2021 Veeva R&D and Quality ...

2021-09-14 11:03:00

Veeva Systems Inc., 2021 Veeva R&D and Quality Summit Connect, Oct 14, 2021.

Neutral

Vericel Corporation Presents at Morgan Stanley ...

2021-09-10 03:17:00

Vericel Corporation Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 04:15 PM. Venue: New Windsor, United Stat...

Negative

Vericel Corporation Appoints Patrick J. Fowler ...

2021-09-07 12:30:00

Vericel Corporation announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy, effective Sep...

Neutral

Vericel Corporation has filed a Shelf Registration.

2021-08-27 00:00:00

Vericel Corporation has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Se...

Negative

Vericel Corporation has filed a Follow-on Equit...

2021-08-27 00:00:00

Vericel Corporation has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common...

Positive

Vericel Corporation Raises Revenue Guidance for...

2021-08-04 12:00:00

Vericel Corporation raised revenue guidance for the year 2021. For the year, the company expects total net revenue to be in the range of $168 ...

Neutral

Vericel Corporation, Q2 2021 Earnings Call, Aug...

2021-07-21 12:32:00

Vericel Corporation, Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Vericel Corporation to Report Q2, 2021 Results ...

2021-07-21 12:30:00

Vericel Corporation announced that they will report Q2, 2021 results on Aug 04, 2021

Neutral

Vericel Corporation Presents at Stephens Annual...

2021-07-10 06:42:00

Vericel Corporation Presents at Stephens Annual Investment Conference, Nov-29-2021 . Venue: Omni Nashville Hotel, 250 Fifth Avenue South, Nash...

Neutral

Vericel Corporation has filed a Shelf Registration in the amount of $78.43 million.

2022-05-06 00:00:00

Vericel Corporation has filed a Shelf Registration in the amount of $78.43 million. Security Name: Common Stock Securities Offered: 2,750,000 Transaction Features: ESOP Related Offering

Neutral

Vericel Corporation Reaffirms Earnings Guidance for the Year 2022

2022-05-04 11:55:00

Vericel Corporation reaffirmed earnings guidance for the year 2022. Total net revenue for 2022 expected to be in the range of $178 to $189 million. Gross margin expected to be approximately 70%.

Neutral

Vericel Corporation, Q1 2022 Earnings Call, May 04, 2022

2022-04-20 12:30:00

Vericel Corporation, Q1 2022 Earnings Call, May 04, 2022

Neutral

Vericel Corporation, Annual General Meeting, Apr 27, 2022

2022-03-17 12:27:00

Vericel Corporation, Annual General Meeting, Apr 27, 2022, at 09:00 US Eastern Standard Time. Agenda: To consider election of directors; to approve, on an advisory basis, the compensation of Vericel Corporation’s named executive officers; to ratify the appointment of PricewaterhouseCoopers LLP as Vericel Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to approve the adoption of Vericel Corporation’s 2022 Omnibus Incentive Plan.

Neutral

Vericel Corporation - Shareholder/Analyst Call

2022-03-17 12:27:00

AGM

Positive

Vericel Corporation Announces Plans for A New Cell Therapy Manufacturing Facility to Support Long-Term Growth

2022-02-02 21:05:00

Vericel Corporation announced that it has entered into a long-term lease agreement for a new cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington, Massachusetts. The new facility, which will include approximately 125,000 square feet of manufacturing, laboratory, and office space, will significantly increase the Company’s cell therapy manufacturing capacity to support the long-term growth of MACI® (autologous cultured chondrocytes on porcine collagen membrane) and Epicel® (cultured epidermal autografts). The Network Drive facility is expected to be completed in 2024, with commercial manufacturing expected to begin in 2025. The Network Drive Campus is designed and operated in accordance with existing LEED Gold and Fitwel Level 2 certifications and the new facility will be included in those certifications.

Neutral

Vericel Corporation Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 10:00 AM

2021-11-12 12:04:00

Vericel Corporation Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 10:00 AM. Speakers: Dominick C. Colangelo, CEO, President & Director.

Neutral

Vericel Corporation Provides Earnings Guidance for the Full Year of 2021

2021-11-09 12:40:00

Vericel Corporation provided earnings guidance for the full year of 2021. For the year, the company's total net revenue is now expected to increase 27%-30% to approximately $158 million-$161 million.

Neutral

Vericel Corporation to Report Q3, 2021 Results on Nov 09, 2021

2021-10-21 12:30:00

Vericel Corporation announced that they will report Q3, 2021 results on Nov 09, 2021

Neutral

Vericel Corporation, Q3 2021 Earnings Call, Nov 09, 2021

2021-10-21 12:30:00

Vericel Corporation, Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021

2021-10-14 22:02:00

Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021.

Neutral

Vericel Corporation Presents at 2021 Veeva R&D and Quality Summit Connect, Oct-14-2021 01:30 PM

2021-09-14 11:35:00

Vericel Corporation Presents at 2021 Veeva R&D and Quality Summit Connect, Oct-14-2021 01:30 PM. Speakers: Craig Gassman, Sr. Director, Corporate Information Systems.

Neutral

Veeva Systems Inc., 2021 Veeva R&D and Quality Summit Connect, Oct 14, 2021

2021-09-14 11:03:00

Veeva Systems Inc., 2021 Veeva R&D and Quality Summit Connect, Oct 14, 2021.

Neutral

Vericel Corporation Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 04:15 PM

2021-09-10 03:17:00

Vericel Corporation Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 04:15 PM. Venue: New Windsor, United States. Speakers: Dominick C. Colangelo, CEO, President & Director.

Negative

Vericel Corporation Appoints Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy

2021-09-07 12:30:00

Vericel Corporation announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy, effective September 7, 2021. Mr. Fowler joins Vericel with over 15 years of business development, strategy and commercial operations experience in the biotech and medical technology industries. Most recently, Mr. Fowler served as Head, North America Strategy, Operations & New Product Development for Sanofi, formerly Genzyme Corporation. During his tenure at Sanofi, he also served as Head, North America Business Development, Specialty Care, as well as Head of Biosurgery Business Development & Portfolio Strategy. Previously, Mr. Fowler served in a number of corporate development roles at Genzyme.

Neutral

Vericel Corporation has filed a Shelf Registration.

2021-08-27 00:00:00

Vericel Corporation has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration

Negative

Vericel Corporation has filed a Follow-on Equity Offering in the amount of $200 million.

2021-08-27 00:00:00

Vericel Corporation has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering

Positive

Vericel Corporation Raises Revenue Guidance for the Year 2021

2021-08-04 12:00:00

Vericel Corporation raised revenue guidance for the year 2021. For the year, the company expects total net revenue to be in the range of $168 million to $171 million, compared to previous guidance of approximately $165 million to $168 million.

Neutral

Vericel Corporation, Q2 2021 Earnings Call, Aug 04, 2021

2021-07-21 12:32:00

Vericel Corporation, Q2 2021 Earnings Call, Aug 04, 2021

Neutral

Vericel Corporation to Report Q2, 2021 Results on Aug 04, 2021

2021-07-21 12:30:00

Vericel Corporation announced that they will report Q2, 2021 results on Aug 04, 2021

Neutral

Vericel Corporation Presents at Stephens Annual Investment Conference, Nov-29-2021

2021-07-10 06:42:00

Vericel Corporation Presents at Stephens Annual Investment Conference, Nov-29-2021 . Venue: Omni Nashville Hotel, 250 Fifth Avenue South, Nashville, Tennessee, United States.

Fundamental Summary

At a high level, the metrics from Vericel's Q1 financial report release were demonstrably negative. Their growth, value, and income factors performance indicate that company management are not executing well their business plan. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. As such, Vericel received an overall score of 53 and a UNDERPERFORM recommendation.

Vericel announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 39.519 million compared to USD 20.014 million a year ago. Operating loss was USD 3.729 million compared to USD 8.358 million a year ago. Net loss was USD 3.786 million compared to USD 8.269 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.18 a year ago. For the half year, total revenue was USD 74.087 million compared to USD 46.692 million a year ago. Operating loss was USD 7.034 million compared to USD 13.434 million a year ago. Net loss was USD 7.075 million compared to USD 12.974 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.29 a year ago.

Business Description

Vericel, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Sector Overview

Vericel is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Vericel's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 240.3 -1.4% 65
Liabilities 67.8 -7.4% 51
Price to Book 6.8 -37.5% 61
Cash & Equivalents 55.7 -18.5% 53
Equity 172.5 1.2% 56
EBITDA -1.7 -170.3% 44
Total Revenues 157.7 1.0% 76
Parameter Value Change Score
Return on Equity -7.2 -47.0% 82
Net Cashflow 3.5 -90.0% 64
Capital Expenditure -8.7 -9.3% 59
Asset Turnover 0.7 0.4% 73
Free Cashflow 0.3 -35.2% 46

* All values are TTM

The below chart reflects Vericel's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Vericel's peer average final assessment score stands on 66.0, Vericel's score is 53.

  •  VCEL
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 1 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 2 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 3 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 5 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 6 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 7 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 8 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 9 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 10 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 11 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 12 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 13 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Vericel's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Vericel's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 31.

Bearish 31
Close Price 24.36
52W Low 22.88
52W High 59.75
5D MA 25.18
50D MA 28.05
200D MA 37.59
MACD -0.96
RSI 39.72
STOCH 36.36

Balance Sheet Analysis

Vericel's recently published balance sheet showed overall, underwhelming numbers. Both Liabilities and Cash & Equivalents were particularly concerning. In terms of liabilities, Vericel published uninspiring results. Their reported liabilities were 67.8, representing a -7.4% change from the previous report. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Therefore, we rated their liabilities movement with a score of 51. Also, Vericel did a poor job related to managing cash and cash equivalents this period, which stood at 55.7, representing a -18.5% change from the previous filing. Their anemic growth in cash and cash equivalents, specifically in contrast to their industry peers' performance, should hurt their stock price. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 53. At the same time, one balance sheet metric, Assets, was actually strongly positive. Vericel assets on their balance sheet, moved to 240.3, which is a -1.4% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Therefore, its asset component earned a score of 65. Consequently, their balance sheet earned a rank of 57.

Parameter Value Change Score
Assets 240.3 -1.4% 65
Liabilities 67.8 -7.4% 51
Price to Book 6.8 -37.5% 61
Cash & Equivalents 55.7 -18.5% 53
Equity 172.5 1.2% 56
* All values are TTM

The below chart describes Vericel's performance as reflected on its balance sheet with respect to its peers. While Vericel received a balance sheet score of 57, the average of its peers stands on 65.0.

  •  VCEL
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 1 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 2 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 3 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 5 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 6 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 7 1
Immatics N.V. 538.7M 56 70 84 95 73 76 8 1
Agenus Inc. 520.5M 73 62 37 55 60 54 9 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 10 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 11 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 12 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 13 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Vericel's income statement report highlighted several concerning metrics. Vericel's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -1.7, which represents a -170.3% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Their EBITDA metrics are even more problematic when compared to their peers. Therefore, their EBITDA component earned a score of 44. Also, Vericel's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. As a result, their revenue efficiency earned a score of 76. On the other hand, Return Factors, jumped out as looking rather positive. Return factors metrics and ratios were exceptional in this report. Vericel reported a return on equity (ROE) ratio of -7.2, representing a change of -47.0% from the last report. These numbers show that management has successfully encouraged growth while managing ROE and ROA metrics, especially relative to their peers. Therefore, its return factors component earned a score of 82. Therefore, its income statement earned a grade of 56.

Parameter Value Change Score
EBITDA -1.7 -170.3% 44
Total Revenues 157.7 1.0% 76
Return on Equity -7.2 -47.0% 82
* All values are TTM

The below chart describes Vericel's performance as reflected on its income statement with respect to its peers. While Vericel received a income statement score of 56 , the average of its peers stands on 69.0.

  •  VCEL
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 1 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 2 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 3 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 5 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 6 1
CTI BioPharma Corp. 603.6M 84 50 62 59 7 1
Immatics N.V. 538.7M 37 93 53 77 8 1
Agenus Inc. 520.5M 57 83 45 74 9 1
Vaxart, Inc. 440.0M 99 51 72 68 10 1
MiMedx Group, Inc. 391.5M 87 43 83 59 11 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 12 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 13 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Overall, Vericel's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Vericel's published asset turnover numbers were encouraging and reflected management's balanced change strategy. Vericel recorded asset turnover of 0.7, which represents a 0.4% change from the previous report. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Correspondingly, their asset turnover movement received a grade of 73. Also, Vericel's management was effective in improving their net cash flow, which now sits at 3.5 and represents a -90.0% change from the previous report. The company is headed in the right direction regarding business priorities, exhibiting prudent net cash flow management and growth. Consequently, their net cash flow movement received a grade of 64. On the other hand, Free Cash flow, jumped out as looking rather underwhelming. Free cash flow numbers published by Vericel were 0.3, which was a -35.2% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. their free cash flow situation appears to be much weaker than their peers. Management needs to do a better job balancing cash flow, asset growth, and resources allocations in general. Its free cash flow movement, therefore, received a grade of 46. Consequently, their cash flow earned a score of 65.

Parameter Value Change Score
Net Cashflow 3.5 -90.0% 64
Capital Expenditure -8.7 -9.3% 59
Asset Turnover 0.7 0.4% 73
Free Cashflow 0.3 -35.2% 46
* All values are TTM

The below chart describes Vericel's performance as reflected on its cash flow with respect to its peers. While Vericel received a cash flow score of 65, the average of its peers stands on 71.0.

  •  VCEL
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 1 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 2 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 3 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 5 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 6 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 7 1
Immatics N.V. 538.7M 82 95 56 99 86 8 1
Agenus Inc. 520.5M 57 43 52 77 58 9 1
Vaxart, Inc. 440.0M 72 56 53 38 65 10 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 11 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 12 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 13 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.